NIMS’ Acceleration Therapeutic Platform: Potential Non-Invasive Home Treatment of Coronary Artery Disease

MIAMI, Fla.--(BUSINESS WIRE)--Marvin A Sackner, M.D., CEO, Chairman of the Board, Non-Invasive Monitoring Systems, Inc. (NIMS) (OTCBB:NIMU) announced that Professor Masatoshi Fujita and associates, Shiga University of Medical Sciences, Kyoto University Graduate School of Medicine, Kitano Hospital, Japan presented a paper on NIMS’ Whole Body Periodic Acceleration (WBPA) technology at the European Society of Cardiology meeting held in Munich, Germany August 30 to September 3, 2008. Their paper entitled “Novel Treatment with Periodic Acceleration with a Horizontal Motion Platform for Anginal Patients” was aimed at demonstrating the effectiveness of daily WBPA treatments on these patients based on previous work that showed this passive exercise technology was associated with increased nitric oxide release and improved arterial function.

“Novel Treatment with Periodic Acceleration with a Horizontal Motion Platform for Anginal Patients”

Dr. Sackner also indicated that Professor Fujita’s team used NIMS first generation device in the study, but for continuing studies have elected to use the new NIMS model which was designed for in-home use. This new model, called Exer-Rest^® is a Class 2a CE 0120, non-invasive, acceleration platform and can be marketed and sold internationally but is not yet approved by FDA for marketing in the United States. The Exer-Rest® produces WBPA through repetitive head-foot movements of the body at 140 times per minute over a period of 45 minutes.

The Fujita study involved twenty treatments (45 minutes each) in six patients with angina over a four week period. These treatments produced major cardiac benefits compared to measurements taken prior to treatment and compared to six additional anginal patients who received conventional medical treatment. Benefits resulting from WBPA treatments included significantly increased exercise time prior to developing electrocardiographic abnormalities during cardiac stress tests, decreased areas of damaged heart muscle on nuclear imaging, and decreased volume of the left heart chamber. The authors concluded “Novel treatment with application of repeated periodic acceleration enhances exercise tolerance in anginal patients through central and peripheral effects. The development of such a therapeutic modality will open a new field of the treatment of anginal patients.”

Dr. Sackner commented, “The study results need to be replicated in a larger group of patients but the dramatic magnitude of the beneficial improvements and the lack of side-effects with WBPA treatments promises to be an innovative approach to the home care of patients with coronary artery disease.”

The Company plans a United States FDA submission to support the intended use of the Exer-Rest® as an aid to improve circulation and to provide temporary relief of aches and pains.

Further information on the Company can be obtained at www.nims-inc.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.